We are live on ! Find out more
PACB icon

Pacific Biosciences
PACB

256 hedge funds and large institutions have $4.2B invested in Pacific Biosciences in 2021 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 87 increasing their positions, 79 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

28% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 40

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

10% more repeat investments, than reductions

Existing positions increased: 87 | Existing positions reduced: 79

4% more funds holding

Funds holding: 246 → 256 (+10)

3% more call options, than puts

Call options by funds: $21M | Put options by funds: $20.4M

1.87% less ownership

Funds ownership: 94.96% → 93.09% (-1.9%)

13% less capital invested

Capital invested by funds: $4.83B → $4.2B (-$629M)

Holders
256
Holders Change
+10
Holders Change %
+4.07%
% of All Funds
3.94%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.08%
New
51
Increased
87
Reduced
79
Closed
40
Calls
$21M
Puts
$20.4M
Net Calls
+$570K
Net Calls Change
+$16.2M

Top Buyers

1
AIM
ARK Investment Management
Florida
+$88.3M
2
Invesco
Invesco
Georgia
+$74.9M
3
NAMA
Nikko Asset Management Americas
New York
+$61.9M
4
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group
Japan
+$61.9M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$44.8M

Top Sellers

1
HA
HHLR Advisors
Cayman Islands
-$23.3M
2
Westfield Capital Management
Westfield Capital Management
Massachusetts
-$21.2M
3
EAM
Eagle Asset Management
Florida
-$14.9M
4
SIG
Senator Investment Group
New York
-$14.1M
5
PAMS
Pictet Asset Management (Switzerland)
Switzerland
-$13M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIM
1
ARK Investment Management
Florida
$540M +$88.3M +3,660,028 +16%
Vanguard Group
2
Vanguard Group
Pennsylvania
$406M +$44.8M +1,858,227 +10%
BlackRock
3
BlackRock
New York
$339M +$10.5M +436,273 +3%
JSP
4
Jackson Square Partners
California
$297M -$809K -33,502 -0.2%
Capital International Investors
5
Capital International Investors
California
$248M +$17.2M +712,191 +6%
NAMA
6
Nikko Asset Management Americas
New York
$245M +$61.9M +2,567,023 +27%
Sumitomo Mitsui Trust Group
7
Sumitomo Mitsui Trust Group
Japan
$244M +$61.9M +2,567,023 +27%
SM
8
SB Management
United Arab Emirates
$167M – – –
CC
9
Casdin Capital
New York
$163M – – –
T. Rowe Price Associates
10
T. Rowe Price Associates
Maryland
$118M +$2.04M +84,468 +1%
William Blair Investment Management
11
William Blair Investment Management
Illinois
$112M +$33.2M +1,374,633 +34%
BBA
12
Baker Bros. Advisors
New York
$111M – – –
State Street
13
State Street
Massachusetts
$85.1M -$2.73M -112,957 -3%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$75.8M +$5.27M +218,252 +6%
Capital World Investors
15
Capital World Investors
California
$69.4M – – –
Invesco
16
Invesco
Georgia
$65.4M +$74.9M +3,103,297 +3,355%
Goldman Sachs
17
Goldman Sachs
New York
$54.7M +$7.48M +309,978 +13%
SEI Investments
18
SEI Investments
Pennsylvania
$54.7M +$3.53M +146,263 +6%
Ameriprise
19
Ameriprise
Minnesota
$51.2M +$6.76M +280,209 +13%
FCM
20
Farallon Capital Management
California
$41.9M +$1.28M +53,238 +3%
Northern Trust
21
Northern Trust
Illinois
$40.6M -$7.69M -318,587 -14%
Macquarie Group
22
Macquarie Group
Australia
$38.9M +$40.8M +1,692,396 +816%
Fidelity Investments
23
Fidelity Investments
Massachusetts
$36.7M +$36.9M +1,528,880 +580%
Norges Bank
24
Norges Bank
Norway
$35.3M +$12.8M +532,100 +45%
Charles Schwab
25
Charles Schwab
California
$32.6M +$3.51M +145,480 +10%
1
2 3 4 5

PACB Hedge Fund Activity: Q4 2021 in Review

256 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q4 2021, worth a combined $4.2B — down 13% from $4.83B a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new PACB positions and 40 closed out — a net gain of 11 holders — while 87 added to existing stakes and 79 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $88.3M. The largest seller was HHLR Advisors, exiting entirely with an estimated $23.3M sold.

  • 256 institutional investors held Pacific Biosciences (PACB) as of Q4 2021, up from 246 in Q3 2021.
  • Funds reported $4.2B of Pacific Biosciences stock for Q4 2021, down 13% quarter-over-quarter.
  • 51 funds opened new Pacific Biosciences positions in Q4 2021 and 40 closed out, a net change of +11 holders.
  • The largest Pacific Biosciences buyer in Q4 2021 was ARK Investment Management, an estimated $88.3M added.
  • The largest Pacific Biosciences seller in Q4 2021 was HHLR Advisors, an estimated $23.3M sold.

Based on aggregated 13F filings for Q4 2021.